Lotilaner ophthalmic solution 0.25% (brand name: Xdemvy, Tarsus Pharmaceuticals) is the first drug approved by the U.S. FDA in July 2023 for the treatment of blepharitis caused by Demodex mite infestation 2).
Demodex blepharitis (DB) is the most common type of blepharitis, affecting approximately 25 million people in the United States 2). 99.2% of confirmed cases have one or more symptoms, and over 77% of patients report negative impacts on daily life 2).
Before 2023, DB treatment was limited to symptomatic therapies such as warm compresses, eyelid hygiene, and tea tree oil (TTO). Although these help relieve symptoms, they do not directly kill Demodex mites 2). Lotilaner is the first approved drug targeting the mites, enabling a fundamental treatment.
Lotilaner belongs to the isoxazoline class and selectively inhibits insect and mite γ-aminobutyric acid (GABA) receptor-gated chloride channels 2). It has been confirmed to have no effect on mammalian GABA-Cl channels even at concentrations 1,100 times the clinical dose (30 μM) 2).
Demodex blepharitis is a chronic inflammation of the eyelid margin caused by excessive infestation of Demodex mites in the eyelash follicles and meibomian glands. A characteristic diagnostic finding is the presence of cylindrical dandruff called “collarettes” at the base of the eyelashes, which causes symptoms such as itching, dryness, and foreign body sensation. The prevalence increases with age, and Demodex mites are detected in nearly all individuals over 70 years old.
Typical complaints include itching, dryness, foreign body sensation, and burning of the eyelids 2). Blurred vision and eye fatigue may also occur. Symptoms overlap with dry eye, but dry eye treatment alone does not improve DB symptoms 2).
Characteristic Findings of Demodex Blepharitis
Cylindrical dandruff: Cylindrical waxy deposits at the base of the eyelashes, a pathognomonic sign of DB 2). Composed of partially digested epithelial cells, mite excrement, and eggs.
Eyelid margin erythema: Redness and swelling of the eyelid margin 2).
Eyelash abnormalities: Loss or misdirection of eyelashes may occur 2).
Meibomian gland dysfunction: Demodex involvement is suggested, but a direct causal relationship has not been proven 3).
Findings in Advanced Cases
The cause of DB is excessive infestation by Demodex mites. Two species of Demodex that parasitize humans are known.
Demodex folliculorum primarily inhabits eyelash follicles and directly damages epithelial cells at the follicle base. This damage causes reactive hyperkeratosis, leading to the formation of cylindrical dandruff 3). Demodex brevis inhabits sebaceous and meibomian glands, physically obstructing the glands and inducing granulomatous reactions 3).
The harmful effects of Demodex are due to three mechanisms 2).
Infestation rates increase with age, reaching 13% in children aged 3–15 years, 84% in those over 60, and nearly 100% in those over 701). The mite life cycle from egg to adult is estimated at 14–23 days3).
The diagnosis of DB is based on the identification of collarettes.
Diagnostic procedure:
Note: Even if mites are not detected by epilation, some cases may only show D. brevis upon meibomian gland expression. Sometimes the diagnosis is only made by microscopic examination of expressed material, even without visible signs of Demodex.
Treatment success is evaluated by the disappearance of collarettes (grade 0: ≤2 lashes, grade 1: ≤10 lashes) and resolution of erythema3). Complete eradication of mites is not necessarily the goal; some propose restoring the balance of the commensal state3).
Dosage and Administration: Instill 1 drop in each eye twice daily for 6 weeks (42 days)2). The 6-week treatment period is designed to cover at least 2 cycles of the mite life cycle (14–23 days)2).
| Trial | Collarette Resolution | Mite Eradication |
|---|---|---|
| Saturn-1 | 44% vs 7.4% | 67.9% vs 17.6% |
| Saturn-2 | 56% vs 12.5% | 51.8% vs 14.6% |
In the integrated results of the Saturn-1 and Saturn-2 trials, 83.6% of the lotilaner group achieved a clinically meaningful reduction in collarettes (≤10) at day 432). The vehicle group was 27.9%2). In the 1-year extension study, the lotilaner group maintained superiority over the vehicle group3).
A meta-analysis (4 trials, 891 patients) confirmed significant superiority of lotilaner1).
| Endpoint | RR (95% CI) |
|---|---|
| Collarette reduction | 3.09 (2.65-3.60) |
| Mite eradication | 3.80 (2.88-5.01) |
| Erythema resolution | 3.16 (2.18-4.58) |
Comfort upon instillation was not different from the vehicle group (RR=1.03, p=0.26)1). The safety profile was comparable to the vehicle group1).
| Main adverse effects | Incidence |
|---|---|
| Instillation site pain/burning sensation | Approximately 10% |
| Chalazion/hordeolum | <2% |
| Punctate keratitis | <2% |
Existing Treatment Options
Tea tree oil (TTO): 4-Terpineol (T4O) is the active ingredient. 50% TTO eyelid wipes are used in clinics, but high-concentration home use is not safe 3). T4O has been reported to be toxic to meibomian gland epithelial cells 3)
Ivermectin: Oral administration reduces mite counts and improves tear film stability. Topical ivermectin 1% cream is also effective but may cause discomfort 3)
Warm compresses and eyelid hygiene: Useful for symptom relief but do not directly kill mites 2)
Stepwise Treatment Approach
Mild DB: Implement strict eyelid hygiene (TTO-containing wipes, warm compresses) for 4–6 weeks 3)
Moderate to severe DB: Administer lotilaner ophthalmic solution 0.25% twice daily for 6 weeks 2)
Recurrent cases: Consider an additional 6-week course. Advise maintenance of eyelid hygiene for long-term management
In clinical trials, 6 weeks of treatment resulted in collarette resolution rates of 44–56% and mite eradication rates of 52–68%. A “clinically meaningful improvement” (reduction to 10 or fewer collarettes) was achieved in approximately 83% of patients. However, since Demodex also resides on facial skin, reinfestation is possible, and long-term follow-up is important. Additional treatment courses may be considered for recurrence.
Tea tree oil (TTO) has been used for Demodex treatment but is not FDA-approved. Its active ingredient, 4-terpineol (T4O), has been reported to be toxic to meibomian gland epithelial cells, raising safety concerns with high concentrations. Lotilaner selectively inhibits mite GABA receptors, minimizing effects on human tissues, and its safety has been confirmed in clinical trials. However, no direct comparative clinical trials have been conducted.
Lotilaner is an isoxazoline compound that selectively inhibits GABA receptor-gated chloride channels in insects and mites 2).
In the normal nervous system of mites, GABA receptor-mediated chloride ion influx causes hyperpolarization of the cell membrane, generating inhibitory postsynaptic potentials. When lotilaner inhibits this channel, the mite loses normal muscle relaxation and becomes spastically paralyzed 2). Paralyzed mites cannot feed, leading to starvation and death 2).
Lotilaner has a molecular weight of 596.76 g/mol and high lipophilicity (logP = 5.3) 2). This lipophilicity is thought to allow preferential uptake into the lipid-rich hair follicle lipids of the eyelid margin where mites reside 2)3).
Demodex mites lack an internal digestive system and secrete proteases and lipases to digest epithelial cells and sebum externally. Direct damage to the hair follicle base by D. folliculorum causes reactive hyperkeratosis, leading to the formation of collarettes 3). D. brevis physically obstructs the meibomian glands, inducing granulomatous reactions and contributing to MGD 3).
Demodex also acts as a vector for bacteria (especially Bacillus oleronius), triggering inflammatory responses in the host 1). In rosacea patients, delayed-type hypersensitivity reactions are particularly prominent.
Lotilaner selectively acts on mite GABA receptors and has been confirmed to have no effect on mammalian GABA receptors even at concentrations 1,100 times the clinical dose. In clinical trials, no clinically significant effects were observed on corrected visual acuity, corneal staining, intraocular pressure, corneal endothelial cell density, fundus findings, or blood test values. The most common side effect is pain or burning sensation upon instillation (approximately 10%), with no reports of serious adverse events.
Clinical evidence on lotilaner is rapidly accumulating.
A meta-analysis by Awan et al. (4 trials, 891 patients) showed that lotilaner demonstrated significant superiority over vehicle control in all efficacy endpoints 1). Clinically meaningful reduction in collarettes (RR = 3.09), collarette elimination (RR = 5.05), composite cure (RR = 6.75), erythema resolution (RR = 3.16), mite density reduction (RR = 2.58), and mite eradication (RR = 3.80) were all significant 1). The safety profile was comparable to the vehicle group 1).
A review by Davey et al. comprehensively analyzed data from 4 phase 2 trials and 2 phase 3 trials (total 980 patients), suggesting that lotilaner could become the standard treatment for DB 2).
In the TFOS DEWS III report, lotilaner is positioned as the only FDA-approved treatment for Demodex at present 3). In a 1-year extension study, the lotilaner group maintained long-term superiority over the vehicle group 3).
Future challenges:
- Awan B, Elsaigh M, Tariq A, Badee M, Loomba A, Khedr Y, Abdelmaksoud A. A Systematic Review and Meta-Analysis of the Safety and Efficacy of 0.25% Lotilaner Ophthalmic Solution in the Treatment of Demodex Blepharitis. Cureus. 2024;16(1):e52664.
- Davey PG, Farid M, Karpecki P, Gaddie IB, Chan A, Mun J, Neervannan S, Yeu E. Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis. Healthcare. 2024;12:1487.
- TFOS DEWS III Management and Therapy Report. Am J Ophthalmol. 2025;279:297-380.
